Ziftomenib

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the upcoming JMP Securities Hematology and Oncology Summit. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 2:00 p.m. ET / 11:00 a.m. PT on December 2, 2024. A live audio webcast of the fireside chat will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available following the live event. About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). In November 2024, Kura entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed and the companies anticipate submission of a New Drug Application in 2025. Kura is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluating in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at https://kuraoncology.com/ and follow us on X and LinkedIn. Kura Contacts Investors:Pete De SpainExecutive Vice President, Investor Relations &Corporate Communications(858) 500-8833pete@kuraoncology.com Media:Cassidy McClainVice PresidentInizio Evoke Comms(619) 849-6009cassidy.mcclain@inizioevoke.com

Today, a brief rundown of news involving Halozyme and Neurogene, as well as updates from Argenx and Kura Oncology that you may have missed.Halozyme Therapeutics on Friday said it withdrew an offer to buy Evotec after the German drug discovery and contracting company refused to engage in acquisition talks. Halozyme sought to buy Evotec in a deal valuing the firm at 2 billion euros, or about $2.1 billion and, in the months leading up to its proposal, sought to discuss the idea with multiple members of Evotec leadership. But several meeting requests were rejected and it is now become evident that there is no interest in a deal, Halozyme CEO Helen Torley said in a statement. Private equity firm Triton has also shown interest in Evotec, however. It recently acquired a 10% stake and is reportedly exploring a possible buyout. Ben FidlerA study participant who received a gene therapy Neurogene is developing for Rett syndrome has died, the company revealed in a regulatory filing Thursday. Neurogene shared last week that the patient, who was given a high dose of the therapy on Nov. 5, was in critical condition after experiencing a side effect consistent with known risks of gene therapies delivered with an adeno-associated virus, or AAV. On Thursday, Neurogene disclosed the patient has since died from complications of that side effect, a rare and life-threatening hyperinflammatory syndrome associated with high systemic exposure to AAV. The Food and Drug Administration recently allowed Neurogene to continue testing with a lower dose. Ben FidlerArgenx is moving ahead with plans to test its drug efgartigimod in several subtypes of myositis, a group of rare autoimmune diseases that affect a range of organs and muscles. The decision to green light further testing followed Argenxs receipt of efficacy and safety results from the Phase 2 portion of a Phase 2/3 study its been conducting. Treatment with efgartigimod, which Argenx sells as Vyvgart for myasthenia gravis and other rare disorders, led to significant patient improvement compared to placebo in the Phase 2 study, the company said Nov. 20. The news, which lifted Argenx stock, provides another market opportunity for efgartigimod that analysts think could be worth at least $1 billion in peak annual sales. Ned PagliaruloKyowa Kirin is paying Kura Oncology $330 million upfront for rights to an experimental oral leukemia drug now in Phase 1 testing, Kura said Wednesday. Under the terms of the deal, Kura could receive up to $420 million more should ziftomenib reach market for relapsed or treatment-resistant acute myeloid leukemia expressing a mutation called NPM1. The deal also gives Kyowa Kirin opt-in rights to ziftomenib in solid tumors. Kura will lead development and book sales in the U.S. that will be shared with Kyowa Kirin, while Kyowa Kirin will handle those responsibilities outside the U.S. Ziftomenib is a new type of cancer drug that blocks a protein called menin, which when it interacts with a second protein helps diseased leukemia cells survive and reproduce. Jonathan GardnerDouglas Throckmorton, the deputy center director for regulatory programs at the Food and Drug Administration, plans to retire in January after 27 years at the agencys main drugs office. Hes been in his current role, which oversees a wide range of issues, since 2005. In an email to FDA staff, Patrizia Cavazzoni, the director of the agencys Center for Drug Evaluation and Research, said Throckmorton has had an immeasurable impact on public health. Throckmorton first informed Cavazzoni in September of his plans to retire. Ned Pagliarulo '